The New Quad: FDA Approves Gilead’s 4-In-1 HIV Pill Stribild
This article was originally published in The Pink Sheet Daily
Executive Summary
With cost concerns already arising, the sponsor says it is working to ensure the drug is covered by state AIDS Drug Assistance Programs.
You may also be interested in...
With Parity Pricing, Gilead Relies On Genvoya Safety To Convert From Stribild
Genvoya includes a much smaller dose of tenofovir than Stribild, allowing for smaller pills, while its label also includes a number of safety advantages that Gilead can use in marketing.
Gilead: Three HIV Launches Expected In Near-Term Future
Sales are strong, especially for Stribild, but Gilead is planning ahead for the patent expiration of Viread and replacing it in combo regimens with a new formulation of tenofovir that offers enhanced therapeutic benefits.
Deal Watch: Hep C M&A Still Thriving; Plus AstraZeneca/Synairgen, MorphoSys/Merck Serono, ViiV/J&J
Merck beats out bids from AbbVie and Johnson & Johnson for Idenix Pharmaceuticals, gaining possession of three promising HCV drug candidates.